말초신경자극기 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of peripheral nerve stimulators Market

The global peripheral nerve stimulators market was valued at USD 684.7 million in 2025 and is projected to grow from USD 780.1 million in 2026 to USD 1,839.2 million by 2034, registering a CAGR of 11.3% during the forecast period. North America dominated the market with a 67.98% share in 2025, supported by advanced healthcare infrastructure, widespread adoption of neuromodulation therapies, and increasing preference for non-opioid pain management solutions.

Peripheral nerve stimulators (PNS) are advanced neuromodulation devices that deliver controlled electrical impulses to targeted peripheral nerves to reduce pain signals and improve nerve function. These devices are widely used in managing chronic pain, post-surgical pain, post-traumatic pain, neuropathic disorders, and selected neurological conditions. Growing concerns regarding opioid dependency, combined with rising incidences of chronic pain and continuous technological advancements in implantable and wearable devices, are significantly driving market expansion worldwide.

Peripheral Nerve Stimulators Market Trends

One of the major trends influencing the market is the growing shift toward wireless, wearable, and outpatient-friendly peripheral nerve stimulation systems. Manufacturers are introducing compact implantable devices, battery-free technologies, remote programming, smartphone-enabled controls, and wearable stimulators that improve patient comfort while simplifying treatment procedures.

Another emerging trend is the increasing adoption of temporary peripheral nerve stimulation therapies. These systems provide effective pain relief without requiring permanent implantation, making them particularly suitable for post-operative pain management and short-term neurological treatments.

Market Drivers

The primary driver of the peripheral nerve stimulators market is the rising global burden of chronic pain disorders. Millions of patients continue to experience pain despite medications, physical therapy, injections, and conventional treatments. Peripheral nerve stimulation offers a targeted, minimally invasive alternative that reduces dependence on opioid medications while providing long-term pain relief.

Growing awareness among physicians, expanding interventional pain management practices, and the increasing number of trained neuromodulation specialists are further supporting product adoption across hospitals and outpatient care centers.

Market Restraints

Despite favorable growth prospects, high device costs and inconsistent reimbursement policies remain significant barriers to wider adoption. Implantable systems involve substantial procedural and equipment costs, making affordability challenging in emerging economies and regions with limited insurance coverage.

Additionally, physicians may continue recommending conventional therapies such as nerve blocks, radiofrequency ablation, medications, and spinal cord stimulation where reimbursement frameworks are more established.

Market Opportunities

Significant opportunities exist in the development of minimally invasive and wearable peripheral nerve stimulation systems. Temporary and externally powered devices enable treatment in ambulatory surgery centers and specialty pain clinics, expanding access to patients who are unwilling or unsuitable for permanent implants.

Rapid healthcare modernization across Asia Pacific, Latin America, and the Middle East also presents substantial growth opportunities as private hospitals increasingly invest in advanced pain management technologies.

Market Challenges

A major challenge for market participants is generating strong long-term clinical evidence across different pain indications. Healthcare providers and insurance companies require proof of sustained pain relief, improved patient outcomes, and cost-effectiveness before approving broader reimbursement.

Furthermore, successful implantation requires specialized physician training and accurate patient selection, limiting adoption primarily to experienced pain management specialists.

Market Segmentation

Based on product type, the market is divided into implantable peripheral nerve stimulators and external/wearable peripheral nerve stimulators. Implantable systems dominated the market in 2025 due to their longer therapy duration and higher clinical utilization for chronic pain management, while wearable systems are expected to witness faster growth during the forecast period.

By application, chronic pain management accounted for the largest market share in 2025 owing to the increasing prevalence of neuropathic pain and the growing demand for long-term non-pharmacological treatment options. Acute post-surgical pain and neurological disorders are also emerging application areas.

Based on end user, hospitals and ambulatory surgery centers (ASCs) held the leading market share because they possess the necessary infrastructure, imaging capabilities, and trained specialists required for peripheral nerve stimulator implantation.

Regional Outlook

North America remained the largest regional market with a value of USD 465.5 million in 2025. The region continues to benefit from strong adoption of advanced neuromodulation devices, favorable clinical expertise, and increasing demand for opioid-free pain management. The U.S. is expected to remain the primary contributor, reaching approximately USD 488.5 million in 2026.

Europe represents the second-largest regional market, supported by increasing adoption of minimally invasive pain therapies and expanding outpatient procedures across Germany, the U.K., France, Italy, and other developed healthcare systems.

Asia Pacific is expected to register the fastest growth through 2034 due to rising chronic pain prevalence, improving healthcare infrastructure, expanding private hospitals, and growing awareness of advanced neuromodulation therapies across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are also witnessing gradual market expansion as healthcare providers continue investing in specialized pain management technologies and advanced medical devices.

Competitive Landscape

The global peripheral nerve stimulators market is moderately consolidated, with key companies focusing on product innovation, clinical research, physician training, and strategic acquisitions. Leading market participants include SPR Therapeutics, Boston Scientific Corporation, Curonix LLC, Medtronic plc, Abbott Laboratories, Mainstay Medical Holdings plc, Bioventus Inc., BlueWind Medical Ltd., Valencia Technologies Corporation, and Laborie Medical Technologies Corp.

Major companies are expanding their portfolios through minimally invasive, wireless, rechargeable, and wearable stimulation systems to strengthen their competitive position in the rapidly evolving neuromodulation market.

Recent Industry Developments

Recent industry developments demonstrate strong investment in peripheral nerve stimulation technologies. In October 2025, Boston Scientific agreed to acquire Nalu Medical for approximately USD 533 million, strengthening its micro-neuromodulation portfolio. Earlier, Mainstay Medical secured USD 125 million in financing to expand commercialization of its restorative neurostimulation platform. Boston Scientific also strengthened its broader neuromodulation business through the acquisition of Axonics, while the U.S. FDA continued clearing updated versions of the SPRINT Peripheral Nerve Stimulation System to support expanding clinical applications.

Conclusion

The peripheral nerve stimulators market is poised for strong long-term growth as healthcare providers increasingly adopt minimally invasive, non-opioid pain management technologies. Rising chronic pain prevalence, technological innovations, expanding outpatient procedures, and increasing awareness of neuromodulation therapies will continue driving demand. With the market expected to grow from USD 684.7 million in 2025 to USD 1,839.2 million by 2034, peripheral nerve stimulators are set to play an increasingly important role in modern pain management and neurological care worldwide.

Segmentation By Product Type, Application, End-user, and Region

By Product Type * Implantable Peripheral Nerve Stimulators

• External/Wearable Peripheral Nerve Stimulators

By Application * Chronic Pain Management

• Acute Post-surgical & Post-traumatic Pain
• Neurological & Functional Disorders
• Others

By End-user * Hospitals and ASCs

• Specialty Clinics
• Others

By Region * North America (By Product Type, By Application, By End-user, and By Country)

• U.S. (By Product Type)
• Canada (By Product Type)
• Europe (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • Germany (By Product Type)
  • U.K. (By Product Type)
  • France (By Product Type)
  • Spain (By Product Type)
  • Italy (By Product Type)
  • Scandinavia (By Product Type)
  • Rest of Europe (By Product Type)
• Asia Pacific (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • China (By Product Type)
  • Japan (By Product Type)
  • India (By Product Type)
  • Australia (By Product Type)
  • Southeast Asia (By Product Type)
  • Rest of Asia Pacific (By Product Type)
• Latin America (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • Brazil (By Product Type)
  • Mexico (By Product Type)
  • Rest of Latin America (By Product Type)
• Middle East & Africa (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • GCC (By Product Type)
  • South Africa (By Product Type)
  • Rest of the Middle East & Africa (By Product Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Advancements in Peripheral Nerve Stimulators
• 4.2. Prevalence of Key Chronic Conditions, By Key Countries/Regions, 2025
• 4.3. New Product Launchers
• 4.4. Key Industry Developments (Mergers, Acquisitions & Partnerships, and Others)

5. Global Peripheral Nerve Stimulators Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Implantable Peripheral Nerve Stimulators
  • 5.1.2. External/Wearable Peripheral Nerve Stimulators
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Chronic Pain Management
  • 5.2.2. Acute Post-surgical & Post-traumatic Pain
  • 5.2.3. Neurological & Functional Disorders
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals and ASCs
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Peripheral Nerve Stimulators Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Implantable Peripheral Nerve Stimulators
  • 6.1.2. External/Wearable Peripheral Nerve Stimulators
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Chronic Pain Management
  • 6.2.2. Acute Post-surgical & Post-traumatic Pain
  • 6.2.3. Neurological & Functional Disorders
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals and ASCs
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Product Type
  • 6.4.2. Canada
    • 6.4.2.1. By Product Type

7. Europe Peripheral Nerve Stimulators Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Implantable Peripheral Nerve Stimulators
  • 7.1.2. External/Wearable Peripheral Nerve Stimulators
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Chronic Pain Management
  • 7.2.2. Acute Post-surgical & Post-traumatic Pain
  • 7.2.3. Neurological & Functional Disorders
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals and ASCs
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. Germany
    • 7.4.1.1. By Product Type
  • 7.4.2. U.K.
    • 7.4.2.1. By Product Type
  • 7.4.3. France
    • 7.4.3.1. By Product Type
  • 7.4.4. Italy
    • 7.4.4.1. By Product Type
  • 7.4.5. Spain
    • 7.4.5.1. By Product Type
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Product Type
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Product Type

8. Asia Pacific Peripheral Nerve Stimulators Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Implantable Peripheral Nerve Stimulators
  • 8.1.2. External/Wearable Peripheral Nerve Stimulators
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Chronic Pain Management
  • 8.2.2. Acute Post-surgical & Post-traumatic Pain
  • 8.2.3. Neurological & Functional Disorders
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals and ASCs
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. China
    • 8.4.1.1. By Product Type
  • 8.4.2. India
    • 8.4.2.1. By Product Type
  • 8.4.3. Japan
    • 8.4.3.1. By Product Type
  • 8.4.4. Australia
    • 8.4.4.1. By Product Type
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Product Type
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Product Type

9. Latin America Peripheral Nerve Stimulators Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Implantable Peripheral Nerve Stimulators
  • 9.1.2. External/Wearable Peripheral Nerve Stimulators
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Chronic Pain Management
  • 9.2.2. Acute Post-surgical & Post-traumatic Pain
  • 9.2.3. Neurological & Functional Disorders
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals and ASCs
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Product Type
  • 9.4.2. Mexico
    • 9.4.2.1. By Product Type
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Product Type

10. Middle East & Africa Peripheral Nerve Stimulators Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Implantable Peripheral Nerve Stimulators
  • 10.1.2. External/Wearable Peripheral Nerve Stimulators
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Chronic Pain Management
  • 10.2.2. Acute Post-surgical & Post-traumatic Pain
  • 10.2.3. Neurological & Functional Disorders
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Hospitals and ASCs
  • 10.3.2. Specialty Clinics
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. South Africa
    • 10.4.1.1. By Product Type
  • 10.4.2. GCC
    • 10.4.2.1. By Product Type
  • 10.4.3. Rest of the Middle East & Africa
    • 10.4.3.1. By Product Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. SPR Therapeutics, Inc.
  • 11.2.2. Boston Scientific Corporation
  • 11.2.3. Curonix LLC
  • 11.2.4. Medtronic plc
  • 11.2.5. Abbott Laboratories
  • 11.2.6. Mainstay Medical Holdings plc
  • 11.2.7. Bioventus Inc.
  • 11.2.8. BlueWind Medical Ltd.
  • 11.2.9. Valencia Technologies Corporation
  • 11.2.10. Laborie Medical Technologies Corp.